...asked an Allergan executive about emerging competition from Evolus. He played it cool and confident as you'd expect. He stated that although, similar, the two are not interchangeable that subtle differences can be meaningful. How meaningful will be unclear until Jeuveau has been in the field longer. Moreover, he emphasized that the jury is still out on Jeuveau. This is a valid point. High quality clinical data is great to have and piques clinician's interest, but it'll take repeated performance in the intended setting for Jeuveau to be fully validated as equivalent to Botox . . .